Market Overview:
The global selective glucocorticoid receptor modulator market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in the field of selective glucocorticoid receptor modulators. Based on type, the global selective glucocorticoid receptor modulator market is segmented into selective androgen receptor modulators (SARMs), selective estrogen receptor modulators (SERMs), and select progesterone receptor modulators (SPRMs). SARMs are expected to witness high growth during the forecast period owing to their ability to selectively bind and activate ARs present in different tissues such as muscle, bone, fat, and prostate tissue. By application, hospitals are expected to account for the largest share of the global selective glucocorticoid receptormodulator market in 2018. This can be attributedtothe growing demand for these drugs for treating various chronic diseases such as cancer, arthritis,,and asthmain hospitals.
Product Definition:
A selective glucocorticoid receptor modulator (SGRM) is a compound that selectively binds to and activates the glucocorticoid receptor. SGRMs are used to treat various diseases, including asthma, rheumatoid arthritis, and Crohn's disease.
Selective Androgen Receptor Modulators:
The Androgen Receptor (AR) is a protein hormone found in the cells of the testes and ovary. It controls the development, growth, and functioning of certain tissues by binding to testosterone. Different types of selective AR modulators are available in market which can be used for treating different conditions based on symptoms they cause.
Selective Estrogen Receptor Modulators:
Selective Estrogen Receptor Modulators (SERMs) are the new generation of anti-carcinogen drugs. They have a selective action on the estrogen receptor and therefore, target only cancer cells. SERM’s are different from other aromatase inhibitors in that they act as weak partial agonists for the ER-B1 subtype of receptors.
Application Insights:
The others segment dominated the global selective glucocorticoid receptor modulator market in 2017, accounting for 33.3% share of the overall revenue. The segment includes surgeries performed in hospitals and ambulatory surgical centers that do not require an overnight stay at a hospital. These surgeries are generally performed for conditions that do not require a general anesthetic, or if there is another medical condition that may react adversely to anesthesia such as asthma or heart disease.
In addition, these medications are used before and after dental procedures to reduce stress on the body caused by surgery during dental treatment due to their anti-inflammatory properties; they also help reduce pain and swelling caused by inflammation around the mouth area due to sensitivity towards touch sensation at this site which helps minimize anxiety levels associated with dentistry procedures.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period owing to increasing cases of CVDs, cancer, and other diseases. Moreover, rising healthcare expenditure by the government and a large number of R&D activities are also supporting growth in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to various factors such as improving economic conditions leading to rise in disposable income resulting in increased adoption of Selective Estrogen Receptor Modulators (SERM) for treating osteoporosis.
In 2016, China accounted for approximately 25% of global sales on account of high product penetration coupled with rising awareness about Corticosteroids used for treatment purposes along with their side effects & risks associated with them.
Growth Factors:
- Increasing prevalence of chronic diseases such as asthma, arthritis, and Crohn's disease
- Growing demand for better treatment options for chronic diseases
- Rising awareness about the benefits of selective glucocorticoid receptor modulators
- Technological advancements in the field of selective glucocorticoid receptor modulators development
- increasing investment by pharmaceutical companies in research and development of selective glucocorticoid receptor modulators
Scope Of The Report
Report Attributes
Report Details
Report Title
Selective Glucocorticoid Receptor Modulator Market Research Report
By Type
Selective Androgen Receptor Modulators, Selective Estrogen Receptor Modulators, Selective Progesterone Receptor Modulators
By Application
Hospitals, Clinics, Ambulatory Surgical Centers, Others
By Companies
Johnson & Johnson, Pfizer, Roche Holding, Novartis, Merck, Sanofi, AbbVie, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Teva Pharmaceuticals, Johnson & Johnson
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
166
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Selective Glucocorticoid Receptor Modulator Market Report Segments:
The global Selective Glucocorticoid Receptor Modulator market is segmented on the basis of:
Types
Selective Androgen Receptor Modulators, Selective Estrogen Receptor Modulators, Selective Progesterone Receptor Modulators
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Pfizer
- Roche Holding
- Novartis
- Merck
- Sanofi
- AbbVie
- Takeda Pharmaceutical Company
- GlaxoSmithKline plc
- Teva Pharmaceuticals
- Johnson & Johnson
Highlights of The Selective Glucocorticoid Receptor Modulator Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Selective Androgen Receptor Modulators
- Selective Estrogen Receptor Modulators
- Selective Progesterone Receptor Modulators
- By Application:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Selective Glucocorticoid Receptor Modulator Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Selective glucocorticoid receptor modulators (SGRMs) are medications that block the action of glucocorticoids, which are hormones that help control inflammation and stress. SGRMs can be used to treat a variety of conditions, including asthma, rheumatoid arthritis, and chronic pain.
Some of the major companies in the selective glucocorticoid receptor modulator market are Johnson & Johnson, Pfizer, Roche Holding, Novartis, Merck, Sanofi, AbbVie, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Teva Pharmaceuticals, Johnson & Johnson.
The selective glucocorticoid receptor modulator market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Selective Glucocorticoid Receptor Modulator Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Selective Glucocorticoid Receptor Modulator Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Selective Glucocorticoid Receptor Modulator Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Selective Glucocorticoid Receptor Modulator Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Selective Glucocorticoid Receptor Modulator Market Size & Forecast, 2018-2028
4.5.1 Selective Glucocorticoid Receptor Modulator Market Size and Y-o-Y Growth
4.5.2 Selective Glucocorticoid Receptor Modulator Market Absolute $ Opportunity
Chapter 5 Global Selective Glucocorticoid Receptor Modulator Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Selective Glucocorticoid Receptor Modulator Market Size Forecast by Type
5.2.1 Selective Androgen Receptor Modulators
5.2.2 Selective Estrogen Receptor Modulators
5.2.3 Selective Progesterone Receptor Modulators
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Selective Glucocorticoid Receptor Modulator Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Selective Glucocorticoid Receptor Modulator Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Ambulatory Surgical Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Selective Glucocorticoid Receptor Modulator Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Selective Glucocorticoid Receptor Modulator Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Selective Glucocorticoid Receptor Modulator Analysis and Forecast
9.1 Introduction
9.2 North America Selective Glucocorticoid Receptor Modulator Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Selective Glucocorticoid Receptor Modulator Market Size Forecast by Type
9.6.1 Selective Androgen Receptor Modulators
9.6.2 Selective Estrogen Receptor Modulators
9.6.3 Selective Progesterone Receptor Modulators
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Selective Glucocorticoid Receptor Modulator Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Ambulatory Surgical Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Selective Glucocorticoid Receptor Modulator Analysis and Forecast
10.1 Introduction
10.2 Europe Selective Glucocorticoid Receptor Modulator Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Selective Glucocorticoid Receptor Modulator Market Size Forecast by Type
10.6.1 Selective Androgen Receptor Modulators
10.6.2 Selective Estrogen Receptor Modulators
10.6.3 Selective Progesterone Receptor Modulators
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Selective Glucocorticoid Receptor Modulator Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Ambulatory Surgical Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Selective Glucocorticoid Receptor Modulator Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Selective Glucocorticoid Receptor Modulator Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Selective Glucocorticoid Receptor Modulator Market Size Forecast by Type
11.6.1 Selective Androgen Receptor Modulators
11.6.2 Selective Estrogen Receptor Modulators
11.6.3 Selective Progesterone Receptor Modulators
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Selective Glucocorticoid Receptor Modulator Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Ambulatory Surgical Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Selective Glucocorticoid Receptor Modulator Analysis and Forecast
12.1 Introduction
12.2 Latin America Selective Glucocorticoid Receptor Modulator Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Selective Glucocorticoid Receptor Modulator Market Size Forecast by Type
12.6.1 Selective Androgen Receptor Modulators
12.6.2 Selective Estrogen Receptor Modulators
12.6.3 Selective Progesterone Receptor Modulators
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Selective Glucocorticoid Receptor Modulator Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Ambulatory Surgical Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Selective Glucocorticoid Receptor Modulator Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Selective Glucocorticoid Receptor Modulator Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Selective Glucocorticoid Receptor Modulator Market Size Forecast by Type
13.6.1 Selective Androgen Receptor Modulators
13.6.2 Selective Estrogen Receptor Modulators
13.6.3 Selective Progesterone Receptor Modulators
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Selective Glucocorticoid Receptor Modulator Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Ambulatory Surgical Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Selective Glucocorticoid Receptor Modulator Market: Competitive Dashboard
14.2 Global Selective Glucocorticoid Receptor Modulator Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson
14.3.2 Pfizer
14.3.3 Roche Holding
14.3.4 Novartis
14.3.5 Merck
14.3.6 Sanofi
14.3.7 AbbVie
14.3.8 Takeda Pharmaceutical Company
14.3.9 GlaxoSmithKline plc
14.3.10 Teva Pharmaceuticals
14.3.11 Johnson & Johnson
